Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 290-836-4 | CAS number: 90268-36-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1976
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- only 2 doses tested. Allthough not all details on the study design were provided, the study was performed to the highest standards at the time of conduct. In the current study, a concurrent test article, dioctyl calcium sulfosuccinate (DCS) was also tested at 0.5, 1, 1.5 and 2% in the diet.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 976
- Report date:
- 1976
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- Docusate sodium
- EC Number:
- 209-406-4
- EC Name:
- Docusate sodium
- Cas Number:
- 577-11-7
- Molecular formula:
- C20H38O7S.Na
- IUPAC Name:
- sodium 1,4-bis[(2-ethylhexyl)oxy]-1,4-dioxobutane-2-sulfonate
- Details on test material:
- - Name of test material (as cited in study report): Dioctyl Sodium Sulfosuccinate (DSS)
- Physical state: white, waxy solid
- Analytical purity: >97%
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No. of test material: DSS was obtained from American Cyanamid Company as Control Lot #7535
FORM AS APPLIED IN THE TEST (if different from that of starting material): DSS was prepared as a 40% solution in (USP) corn oil.
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Breeding Laboratories
- Age at study initiation: about 2 months
- Housing: individually in hanging wire mesh cages
- Diet (e.g. ad libitum): Wayne Lab Meal ad libitum
- Water (e.g. ad libitum): ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 24±2°C
- Humidity (%): 50±5%
- Photoperiod (hrs dark / hrs light):12/12
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: 40% solution in corn oil
DIET PREPARATION
- Mixing appropriate amounts with (Type of food): 1.0% and 2.0% admixed in Wayne Lab Meal
VEHICLE
- Concentration in vehicle: 40% solution in corn oil - Analytical verification of doses or concentrations:
- not specified
- Details on mating procedure:
- Not provided
- Duration of treatment / exposure:
- dosing from gestational days 6 through 15
- Frequency of treatment:
- continuous in the diet
- Duration of test:
- gestational days 6 through 15: dosing
gestational day 21: killing of the mothers and removing fetuses by cesarean section
Doses / concentrationsopen allclose all
- Dose / conc.:
- 1 other: %
- Remarks:
- nominal in diet; Exp. II-A.
- Dose / conc.:
- 2 other: %
- Remarks:
- nominal in diet; Exp. II-B.
- Dose / conc.:
- 1 074 mg/kg bw/day (actual dose received)
- Remarks:
- 1.0%: calculated compound consumed
- Dose / conc.:
- 1 988 mg/kg bw/day (actual dose received)
- Remarks:
- 2.0%: calculated compound consumed
- No. of animals per sex per dose:
- 43 pregnant female rats in control group
22 pregnant female rats in dose 1.0%
20 pregnant female rats in dose 2.0% - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
Adult rats can tolerate, at least, 1% of DSS in their diets (equivalent to about 600 - 700 mg/kg/day) for 1 year without adverse effects on any of the various parameters tested including histopathology (Fitzhugh and Nelson, 1948). The purpose of this investigation was to evaluate the possible teratogenic effects of DSS when given orally to pregnant rats during periods of gestational development, and examination of offspring for abnormalities .
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes (clinical condition and signs of illness)
- Time schedule: each day
BODY WEIGHT: Yes (weight gain)
- Time schedule for examinations: gestation day 6-15; gestation day 15-21
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes
- Food consumption for each animal determined and mean daily diet consumption calculated as g
food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight
gain data: Yes
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day #21
- Organs examined: Ovaries and uterine content - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: No
- Number of corpora lutea: No
- Number of implantations: Yes
- Number of resorptions: Yes - Fetal examinations:
- - External examinations : Yes (all per litter)
- Soft tissue examinations: No
- Skeletal examinations: Yes: one half of the total number of fetuses
- Head examinations: No
-Visceral examinations: Yes one-half of the total number of fetuses were fixed in Bouin’s fluid for a detailed examination of visceral anomalies, using the slicing method of Wilson - Statistics:
- Maternal body-weight gains, maternal food consumptions and fetal weights were analyzed by Dunnett’s two-sided, multiple comparison test. Frequencies of resorptions and fetal abnormalities among litters were analyzed by the Mann-Whitney U test or the Chi-square test (with Yate’s correction), as appropriate.
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- no effects observed
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Among rats given dietary levels of 2.0% DSS, there were significant depressions in maternal weight-gains.
Rats fed diets containing 1.0% level of DSS showed no significant maternal effects on the various parameters. - Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- Rats fed diets containing 1.0% level of DSS) showed no significant maternal effects on the various parameters. Among rats given dietary levels of 2.0% DSS, there were significant depressions in maternal weight gains.
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- not specified
- Total litter losses by resorption:
- effects observed, treatment-related
- Description (incidence and severity):
- In the 2.0% DSS group 1 pregnancy with total resorptions was observed (No statistical significance). No pregnancy with total resorptions was observed in the control or 1.0% DSS group.
- Early or late resorptions:
- effects observed, treatment-related
- Description (incidence and severity):
- Among rats given dietary levels of 2.0% DSS, there were significant increases in the number of resorptions of 13.7% as compared to the control frequency of 5.6%.
- Dead fetuses:
- no effects observed
- Description (incidence and severity):
- 0.5% occurrence of dead fetuses was seen in the 2.0% DSS group versus 0.7% in the control group. No dead fetuses were observed in the 1.0% DSS group.
- Changes in pregnancy duration:
- not examined
- Changes in number of pregnant:
- not examined
- Details on maternal toxic effects:
- Maternal toxic effects:yes. Remark: 2.0% in the diet
Effect levels (maternal animals)
open allclose all
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- 1 other: %
- Based on:
- act. ingr.
- Remarks:
- in the diet
- Basis for effect level:
- body weight and weight gain
- early or late resorptions
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 074 mg/kg bw/day (actual dose received)
- Based on:
- act. ingr.
- Basis for effect level:
- body weight and weight gain
- early or late resorptions
Results (fetuses)
- Fetal body weight changes:
- no effects observed
- Reduction in number of live offspring:
- no effects observed
- Description (incidence and severity):
- There is no significant reduction in viable fetuses in the dosed animals animals compared to control animals.
- Changes in sex ratio:
- not specified
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- not examined
- Description (incidence and severity):
- There is no postnatal evaluation in an OECD 414 study.
- External malformations:
- effects observed, treatment-related
- Description (incidence and severity):
- Near toxic or toxic dietary levels of 2.0% DSS produced significant incidences of gross abnormalities either among litters (25.0%) or fetal populations (20.2%) as compared to none in the controls. These abnormalities consisted of cranial buble, exencephaly, spina bifida (not significant), microphtalmia or anophtalmia (not significant).
- Skeletal malformations:
- no effects observed
- Visceral malformations:
- effects observed, treatment-related
- Description (incidence and severity):
- The visceral observations confirmed the significance of the exencephalous characteristics and anophtalmia for the group given dietary levels of 2.0% DSS.
- Other effects:
- effects observed, treatment-related
- Description (incidence and severity):
- In the 2.0% DSS group, skeletal observations revealed a significant incidence of variations including incomplete ossification to absence of the various cranial bones, a curved or open vertebral column, and a variety of defects of the vertebrae and ribs.
- Details on embryotoxic / teratogenic effects:
- Details on embryotoxic / teratogenic effects:
See Table 1-4.
Effect levels (fetuses)
open allclose all
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- 1 other: %
- Based on:
- act. ingr.
- Remarks:
- diet
- Sex:
- male/female
- Basis for effect level:
- external malformations
- visceral malformations
- other:
- Remarks on result:
- other: secondary to high maternally toxic dose
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 074 mg/kg bw/day
- Based on:
- act. ingr.
- Remarks:
- diet
- Sex:
- male/female
- Basis for effect level:
- external malformations
- visceral malformations
- other: skeletal variations
Fetal abnormalities
- Abnormalities:
- effects observed, treatment-related
- Localisation:
- external: cranium
- skeletal: skull
- skeletal: rib
- visceral/soft tissue: central nervous system
- visceral/soft tissue: eye
- Description (incidence and severity):
- only at 2.0% dietary level.
Overall developmental toxicity
- Developmental effects observed:
- yes
- Lowest effective dose / conc.:
- 2 other: %
- Treatment related:
- yes
- Relation to maternal toxicity:
- developmental effects as a secondary non-specific consequence of maternal toxicity effects
- Dose response relationship:
- yes
- Relevant for humans:
- no
Any other information on results incl. tables
Table 1. Maternal and fetal results of pregnant rats given various amounts if DSS in their diets during gestational days 6 through 15.
Parameter |
Control |
1.0% DSS |
2.0% DSS |
Maternal |
Group (I-A) |
(II-A) |
(II-B) |
No. of pregnant rats |
43 |
22 |
20 |
No. of pregnancies with total resorptions |
0 |
0 |
1 |
No. of pregnancies with viable fetuses |
43 |
22 |
19 |
Average weight gain of dams with viable fetuses(g): |
|
|
|
Days 6 to 15 |
78 |
86 |
52* |
Days 15 to 21 |
66 |
67 |
77 |
Average, apparent food intake of dams with viable fetuses (g/rat/day): |
|
|
|
Days 6 to 15 |
22.5 |
24.8 |
21.4 |
Days 15 to 21 |
28.6 |
32.1 |
33.4 |
Calculated compound consumed (mg/kg/day) |
-- |
1074 |
1988 |
Litters |
|
|
|
Total number of: implantations |
411 |
203 |
219 |
Resorptions (% occurence) |
23 (5.6) |
8 (3.9) |
30*a (13.7) |
Dead fetuses (% occurrence) |
3 (0.7) |
0 |
1 (0.5) |
Viable fetuses (% occurrence) |
385 (93.7) |
195 (96.1) |
188 (85.5) |
Fetal weight (g) |
4.6 |
5.2 |
4.7 |
Litters size (viable fetuses) |
8.9 |
8.9 |
9.9 |
External major malformations1: No. of litters affected (% occurrence) |
0 |
0 |
5* (25.0) |
No. of fetuses affected (% occurrence) |
0 |
0 |
36*a (20.2) |
* Significantly different from control (p< 0.05)
a Significance by Chi-square, but not Mann-Whitney U test
1 Primarily, exencephaly varying degrees and associated anomalies (See Table 2)
Table 2. Morphological observations of fetuses delivered from rats given DSS in their diets on gestational days 6 through 15.
Morphology |
Control |
1.0% DSS |
2.0% DSS |
External observations1: |
Group (I-A) |
(II-A) |
(II-B) |
Total number examined |
388a |
195 |
189 |
Major anomalies: Adactyly |
0 |
0 |
0 |
Hemimelia |
0 |
0 |
0 |
Schistocelia |
0 |
0 |
2 |
Dome shaped head |
0 |
0 |
0 |
Cranial bubble (1-2mm) |
0 |
0 |
9* |
Exencephaly |
0 |
0 |
18* |
Exencephaly (cleft condition) |
0 |
0 |
7* |
Anencephaly |
0 |
0 |
0 |
Spina bifida |
0 |
0 |
6 |
Macroglossia |
0 |
0 |
0 |
Micro- or anophtalmia |
0 |
0 |
3 |
Defects: Hematoma (subcutaneous) |
2 |
0 |
0 |
Edamatous abdomen |
0 |
0 |
0 |
Tail short & curled |
0 |
0 |
0 |
Abducted fifth digit, left Rear foot |
0 |
0 |
1 |
1 Fetuses may have more than one defect
a Fifty-four fetuses examined grossly only. (Shipment c valid as controls only)
*Significantly different from control (p< 0.05) by Chi-square only
Table 3. Visceral observations of fetuses delivered from rats given DSS in their diets on gestation days 6 through 15.
Visceral observations |
Dose: Control |
1.0 % DSS |
2.0% DSS |
Groups: (I-A) |
(II-A) |
(II-B) |
|
Total number of fetuses examined |
165a |
98 |
91 |
Defects1: Exencephalous characteristics |
0 |
0 |
11* |
Dilated lateral ventricles |
1 |
3 |
5 |
Microphtalmia |
0 |
1 |
0 |
Anolphtalmia |
0 |
0 |
23* |
Retinal foldings |
0 |
0 |
0 |
Anotia or microtia |
0 |
0 |
0 |
Cleft palate |
0 |
0 |
1 |
Situs transversus – aorta, esophagus & stomach |
1 |
0 |
0 |
Intestinal agenesis |
0 |
0 |
0 |
Arch of aorta absent or right sided |
0 |
0 |
0 |
Diaphragmic hernia |
0 |
0 |
1 |
Dilated renal pelves |
2 |
0 |
3 |
Ectopic kidneys(s) &/or variation in size |
1 |
0 |
0 |
Renal agenesis |
0 |
0 |
2 |
Dilated ureters |
6 |
0 |
3 |
Adrenal agenesis |
0 |
0 |
1 |
Testes – ectopic or enlarged |
1 |
0 |
1 |
Hermaphroditism |
0 |
0 |
3 |
1Fetuses may have more than one defect
aExcludes 1 fetus lost
*Significantly different from control (p<0.05) by Chi-square only
Table 4. Skeletal observations of fetuses delivered from rats given DSS in their diets on gestation days 6 through 15.
Skeletal observations |
Dose: Control |
1.0 % DSS |
2.0% DSS |
Group (I-A) |
(II-A) |
(II-B) |
|
Total number of fetuses examined |
167a |
97 |
98 |
Defects1: Cranial bones, incomplete to lack of ossification : Nasal |
0 |
0 |
4 |
Frontal |
1 |
0 |
20* |
Parietal |
1 |
1 |
19* |
Interparietal |
1 |
2 |
18* |
Supraoccipital |
0 |
0 |
15* |
Exoccipital |
0 |
0 |
2 |
Atlas |
0 |
0 |
1 |
Zygomatic |
0 |
0 |
1 |
Premaxilla |
0 |
0 |
1 |
Tympanic bullae |
0 |
0 |
5 |
Mandibles |
0 |
0 |
1 |
Hyoid |
0 |
0 |
3 |
Eye orbit, reduction |
0 |
0 |
0 |
Exoccipital, fused to atlas |
0 |
0 |
0 |
Vertebrla column, curved &/or open |
0 |
0 |
5 |
Vertebrae: |
|
|
|
misshapened &/or retarded development |
0 |
0 |
5 |
thoracic, bipartite centra |
2 |
1 |
5 |
lumbar, bipartite centra |
0 |
0 |
2 |
Sternebrae: |
|
|
|
fused |
0 |
0 |
0 |
hypoplastic to absent |
0 |
0 |
1 |
one or two absent |
1 |
0 |
0 |
staircase |
0 |
0 |
3 |
bipartite |
0 |
0 |
2 |
Rib(s): |
|
|
|
accesory |
6 |
5 |
5 |
Absent or less developed |
0 |
0 |
7* |
wavy |
2 |
2 |
0 |
fused |
0 |
0 |
2 |
Pelvic, hypoplastic to absent |
0 |
0 |
0 |
Brachydactyly |
0 |
0 |
0 |
Syndactyly |
0 |
0 |
0 |
Adactyly |
0 |
0 |
0 |
Hemimelia & small scapula |
0 |
0 |
0 |
1Fetuses may have more than one defect
aExcludes 1 fetus destroyed during cleaning process
*Significantly different from control (p<0.05) by Chi-square only
Applicant's summary and conclusion
- Conclusions:
- Subtoxic dietary levels of 1.0% docusate sodium ingested on gestational days 6 through 15 showed no adverse effects on the various maternal or fetal parameters. Near toxic or toxic dietary levels of 2.0% DSS produced significant incidences of resorptions (13.7%) and gross abnormalities either among litters (25.0%) or fetal populations (20.2%) as compared to controls. Interpretation of the results of the present experiments, in which only maternally toxic dose levels induce teratogenicity, indicates no real hazard with the recommended human use of these surfactants.
- Executive summary:
Prenatal developmental toxicity was studied in rats dosed from day 6 to day 15 of gestation by dietary administration of docusate sodium at dose levels of 1.0 and 2.0 % in the diet. Subtoxic dietary levels of 1.0% showed no adverse effects on the various maternal or fetal parameters. Near toxic or toxic dietary levels of 2.0% docusate sodium produced significant depressions in maternal weight-gains and increased incidences of resorptions (13.7%) and gross abnormalities either among litters (25.0%) or fetal populations (20.2%) as compared the controls. These abnormalities consisted primarily of exencephaly of varying degrees with, at times, spina bifida, anophtalmia and associated skeletal defects. The visceral observations confirmed the significance of the exencephalous characteristics and anophtalmia for the group given dietary levels of 2.0%. In this group, skeletal observations revealed a significant incidence of incomplete ossification to absence of the various cranial bones, a curved or open vertebral column, and a variety of defects of the vertebrae and ribs. There were significant depressions in maternal weight gains in the 2.0% DSS-group. Interpretation of the results of the present experiment, in which only maternally toxic dose levels induce teratogenicity, indicates no real hazard with the recommended human use of these surfactants.
The concentration of 1% in the diet is considered as maternal and developmental NOAEL. This dose level corresponded with 1074 mg/kg body weight, as calculated in the study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
